High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer-Reference-Cited by-同舟云学术

High OX-40 expression in the tumor immune infiltrate is a favorable prognostic factor of overall survival in non-small cell lung cancer

Published:2019-12 Issue:1 Volume:7 Page:
ISSN:2051-1426
Container-title:Journal for ImmunoTherapy of Cancer
language:en
Short-container-title:j. immunotherapy cancer

Author:

Massarelli Erminia,Lam Vincent K.,Parra Edwin R.,Rodriguez-Canales Jaime,Behrens Carmen,Diao Lixia,Wang Jing,Blando Jorge,Byers Lauren A.,Yanamandra Niranjan,Brett Sara,Morley Peter,Sharma Padmanee,Allison James,Wistuba Ignacio I.,Heymach John V.

Funder

National Cancer Institute

Publisher

BMJ

Subject

Cancer Research,Pharmacology,Oncology,Molecular Medicine,Immunology,Immunology and Allergy

Link

http://link.springer.com/content/pdf/10.1186/s40425-019-0827-2.pdf

Reference48 articles.

1. Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, et al. Nivolumab versus Docetaxel in advanced squamous-cell non-small-cell lung Cancer. N Engl J Med. 2015;373(2):123–35 PubMed PMID: 26028407. Pubmed Central PMCID: 4681400.

2. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, et al. Nivolumab versus Docetaxel in advanced nonsquamous non-small-cell lung Cancer. N Engl J Med. 2015;373(17):1627–39 PubMed PMID: 26412456.

3. Herbst RS, Baas P, Kim DW, Felip E, Perez-Gracia JL, Han JY, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50 PubMed PMID: 26712084.

4. Reck M, Rodriguez-Abreu D, Robinson AG, Hui R, Csoszi T, Fulop A, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung Cancer. N Engl J Med. 2016;375(19):1823–33 PubMed PMID: 27718847.

5. Sharma P, Allison JP. Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell. 2015;161(2):205–14 PubMed PMID: 25860605. Pubmed Central PMCID: PMC5905674. Epub 2015/04/11.

Cited by 42 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Overcoming Resistance to Checkpoint Inhibitors with Combination Strategies in the Treatment of Non-Small Cell Lung Cancer;Cancers;2024-08-22

2. Uncovering the Expression Pattern of the Costimulatory Receptors ICOS, 4-1BB, and OX-40 in Exhausted Peripheral and Tumor-Infiltrating Natural Killer Cells from Patients with Cervical Cancer;International Journal of Molecular Sciences;2024-08-12

3. Making the effect visible – OX40 targeting nanobodies forin vivoimaging of activated T cells;2024-08-09

4. Immune checkpoint expression as prognostic biomarker candidates in non‐small cell lung carcinoma patients;Journal of Surgical Oncology;2024-07-07

5. Prognostic Role of OX40, LAG-3, TIM-3 and PD-L1 Expression in Bone and Soft Tissue Sarcomas;Journal of Clinical Medicine;2024-06-20